Imagine giving a powerful medicine to a 20-year-old versus an 80-year-old; the older body often reacts differently and can't handle the same dose. This project creates a better way to check an older person's overall health first to figure out the exact right drug amount. It aims to keep the treatment effective while stopping the harsh side effects that often force elderly patients to quit their medicine.
Older breast cancer patients face a higher risk of adverse events and treatment discontinuation when using standard doses of CDK 4/6-inhibitors. There is currently a lack of standardized, evidence-based dosing guidelines tailored to the geriatric population.
A pragmatic, randomized controlled clinical trial and a comprehensive geriatric assessment (CGA) process for dose optimization.
If you are a drug developer dealing with high treatment discontinuation rates in elderly populations — this project developed a geriatric assessment method that optimizes CDK 4/6-inhibitor dosing. This ensures patients over 70 stay on therapy longer by reducing adverse events.
If you are a clinic dealing with unpredictable patient reactions to standard cancer doses — this project developed a standardized, individualized dosing approach. This allows for safer treatment of the 495 female and male patients targeted in the study.
If you are a software provider dealing with a lack of evidence-based dosing guidelines for the elderly — this project developed a pragmatic clinical study model. This data can be integrated into tools to help doctors choose doses based on comprehensive geriatric assessments.
Based on available project data, specific pricing or implementation costs are not provided.
The project uses a decentralized, pragmatic design across 6 European countries, suggesting the methodology is designed for real-world clinical scaling.
Based on available project data, there is no mention of patents or specific licensing terms.
The project follows clinical trial standards for a randomized controlled trial involving patients in 11 different countries.
The project runs from 2023-05-01 to 2028-04-30, spanning a total of 60 months.
The consortium is highly diversified with 21 partners, including a 24% industry ratio (5 companies). The presence of 4 SMEs and 6 research entities alongside 5 universities indicates a strong bridge between academic theory and commercial application, specifically tailored for clinical deployment across 11 countries.
Contact OREBRO LANS LANDSTING in Sweden
Contact us to explore partnership opportunities with the IMPORTANT consortium.
